E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Chronic degenerative Achilles and patella tendinopathy patients, with neovascularisation on USS, who have failed best practice rehabilitation including Eccentric Loading (EL), Heavy Slow Resistance Training (HSR) and Extra-Corporal Shock Wave Therapy (ESWT) will be randomised to one of three injections: 3ml of Marcain Polyamp 0.5% (Placebo) or 10 ml of Marcain Polyamp 0.5%+2.5ml Sodium Chloride 0.9% or 10ml of Marcain Polyamp 0.5%+2.25ml Sodium Chloride 0.9% + 0.25ml Efcortesol 100mg/ml. |
|
E.1.1.1 | Medical condition in easily understood language |
Patients with long term Achilles and knee tendonopathy (tendinitis) who have failed to improve with best practice physiotherapy and shockwave therapy and have new blood vessels growing into the damage |
|
E.1.1.2 | Therapeutic area | Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10000433 |
E.1.2 | Term | Achilles tendinitis |
E.1.2 | System Organ Class | 100000004859 |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10034123 |
E.1.2 | Term | Patellar tendinitis |
E.1.2 | System Organ Class | 100000004859 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Hypothesis 1
High Volume Effect in both the presence and absence of steroid is superior to placebo.
Implications
The literature contains many papers by the same group indicating that the proposed successes may be operator dependent. If we can demonstrate the High Volume Effect to work independently with a simpler technique then Defence Rehabilitation will benefit in a way that is not currently applicable from the literature. Frequently innovative sports medicine procedures have become commonplace without sufficient evidence and at high risk of bias53. The lack of control groups in trials relating to the High Volume Effect desperately needs to be addressed.
|
|
E.2.2 | Secondary objectives of the trial |
Hypothesis 2
HVE without CS is non-inferior to HVE with CS.
Implications
Separating the effect of HVE and CS, two very different mechanisms of action, is vital to further injectable therapy in tendinopathy. By conducting this trial Defence Rehabilitation will provide further evidence for its own pathway and will also be making a significant contribution to the scientific literature.
Hypothesis 3
Specific biomechanical factors will be associated with patella tendinopathy in symptomatic patients during walking and one leg squat assessments.
Implications
The number of participants will also be comparable to previous trials allowing us to build on those findings. Use of our patients in this trial will allow us to confirm if these associations are relevant to the defence population as much of the current data is extrapolated from very specifically trained athletes. Confirmed strategies can then be emphasised throughout Defence. Education of personnel at an early stag |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Chronic Achilles and patella tendinopathy patients Age 18-55 Male No or minimal improvement with physical rehabilitation pathway outlined below Minimum duration of symptoms of 6 months US evidence of neovascularization Patients must be medically downgraded and not deployable
|
|
E.4 | Principal exclusion criteria |
Concurrent alternate lower limb diagnosis Female Anticoagulant medication Previous tendon surgery or injection
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Primary outcomes will be:
a. The Visual Analogue Scale (VAS) for pain. This is a subjective score from the participant on pain level recorded by asking the patient to mark along a 100mm line their pain level with 0mm representing no pain and 100mm maximal pain.
b. Validated Victoria Institute of Sport-Achilles (VISA-A)55 and Victoria Institute of Sport-Patella (VISA-P)1 scores for pain and function. These are validated questionnaires that are widely accepted throughout the literature. They are recommended for use in research to enable direct comparison and use in meta-analyses. The questionnaires are self-explanatory and can be completed by the participant alone.
An administrator not involved with the trial will check questionnaires for basic errors eg missing out part of the form. The questionnaires will be completed in a separate area of the waiting room away from treating clinicians and other participants.
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline, 6 weeks, 3months and 6 months |
|
E.5.2 | Secondary end point(s) |
Secondary outcomes will be:
a. The degree of neovascularisation measured using the modified Ohberg Score2. This will be recoded as follows:
0= No vessels visible 1= 1 vessel mostly anterior to the tendon 2= 1 or 2 vessels throughout the tendon 3= 3 vessels throughout the tendon 4= More than three vessels throughout the tendon
Images will be stored to disk and kept in a locked cabinet within the DMRC Academic Department of Military Rehabilitation.
Scoring will be made by one of the two operators delivering injections either Col A Nicol or Dr I McCurdie who will be blinded to type of injectate as described above.
b. The Functional Activity Assessment (FAA) score which is validated in the military population3. The score being:
FAA 1= Fully Fit FAA 2= Fit for trade and fit for restricted general or military duties FAA 3= Unfit for trade but fit for restricted general or military duties FAA 4= Unfit for all but sedentary duties FAA 5= Off all duties
This is self-reported by the participant.
There will biomechanical evaluation (using kinetics and kinematics) of a patella tendinopathy subgroup nested within the trial at baseline and 6 months follow up only.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline, 6 weeks, 3months and 6 months.
There will be biomechanical evaluation (using kinetics and kinematics) of a patella tendinopathy subgroup nested within the trial at baseline and 6 months follow up only. This will be compared with a group of healthy controls.
There will be a correlational study multiple regression analysis of epidemiological factors that will be used to look for predictors between tendinopathy participants and matched controls. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | 7 |
E.8.9.1 | In the Member State concerned days | 3 |
E.8.9.2 | In all countries concerned by the trial years | 2 |
E.8.9.2 | In all countries concerned by the trial months | 8 |
E.8.9.2 | In all countries concerned by the trial days | 30 |